2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: TX

Poster-Multidisciplinary Care

October 25, 2021

Promising Opportunities to Integrate Health and Wellness Coaching into Comprehensive Care Teams for Patients with Multiple Sclerosis

Background: The impact of unhealthy lifestyle behaviors and comorbidities is a rapidly rising focus in treating patients with Multiple...

Read More →

Poster-Epidemiology and Genetics

October 25, 2021

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More →

Poster-Imaging

October 25, 2021

Could Cerebral Autoregulatory Collapse Explain Cognitive Impairment in MS?

Background: Cognitive impairment occurs in almost 70% of multiple sclerosis (MS) patients. The pathophysiology of this impairment is...

Read More →

Poster-Imaging

October 25, 2021

Prefrontal Metabolism Is Associated with Processing Speed in Multiple Sclerosis: A Calibrated fMRI Study

Background: Cognitive processing speed deficits are common in multiple sclerosis (MS). Despite this, the exact neural mechanism underlying...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis

Background: MOGAD is an emerging inflammatory demyelination disorder of the central nervous system. AZA is one of the commonly used...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy

Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder

Background: Long-term use of B-cell depleting monoclonal antibodies is associated with reduced immunoglobulin (Ig) levels that can...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC